Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration‐Resistant Prostate Cancer (mCRPC)

BACKGROUND. Enhancing the effectiveness of docetaxel for men with metastatic castration‐resistant prostate cancer (mCRPC) is an unmet clinical need. Preclinical studies demonstrated that high‐dose pantoprazole can prevent or delay resistance to docetaxel via the inhibition of autophagy in several so...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Hansen, Aaron R., Tannock, Ian F., Templeton, Arnoud, Chen, Eric, Evans, Andrew, Knox, Jennifer, Prawira, Amy, Sridhar, Srikala S., Tan, Susie, Vera‐Badillo, Francisco, Wang, Lisa, Wouters, Bradly G., Joshua, Anthony M.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Genitourinary Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6738292/
https://ncbi.nlm.nih.gov/pubmed/30952818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0621
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados